-43%

est. 2Y upside i

HealthcareSeries C

Rank

#3165

Sector

Healthcare IT

Est. Liquidity

~3Y

Data Quality

Data: Low

Equity upside is negative across all scenarios due to minimal growth (1.7% YoY), a stale 2019 valuation, and heavy dilution risk.

Last updated: July 3, 2026

Bull (10%)-7%

Exit multiple holds at 3.5x on steady revenue of $36.3M, yielding $127M exit. After 20% dilution, common stock returns -6.6%.

Base (45%)-33%

Exit multiple converges to public comps at 2.5x, exit value $90.8M. After dilution, common stock returns -33.4%.

Bear (45%)-60%

Multiple compresses to 1.5x due to incumbent pressure, exit value $54.5M. After dilution and preference, common stock returns -60%.

Est. time to liquidity~3.0 years

Preference Stack Risk

severe

Funding Intensity

33%

Total funding $35M vs estimated entry $106.5M gives 33% preference overhang, meaning preferred holders capture a large portion of exit proceeds.

Dilution Risk

high

Given low growth and no recent raise, a new funding round within 24 months is likely, diluting common by ~20%.

Secondary Liquidity

none

No secondary market signals; shares are illiquid until a liquidity event.

Questions to Ask at the Interview

Strategic questions based on Verato's data — designed to show you've done your homework.

  • 1

    “How does Verato defend against built-in patient matching from Epic and Oracle?”

  • 2

    “What is the net dollar retention and customer concentration?”

  • 3

    “When does the company anticipate a liquidity event and what triggers it?”

Community

Valuation Sentiment

Our model estimates -43% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.